endo-BCN-Val-cit-PAB-MMAE is a synthetic antibody drug conjugate coupled to an BCN group. It contains a a protease-sensitive Val-Cit dipeptide, and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells. The BCN group can react with azide -tagged compound or biomolecules. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
Usually ships within 24 hours.